ENT 103

Drug Profile

ENT 103

Alternative Names: Radiolabelled ENT-103

Latest Information Update: 07 Apr 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Entropin (CEASED)
  • Class Anaesthetics; Analgesics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 02 Jun 2004 Entropin announces delay in preclinical and clinical trials of ENT 103
  • 15 Mar 2004 ENT 103 is available for licensing (http://www.entropin.com)
  • 08 Mar 2004 Preclinical data from a media release have been added to the Pain pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top